ANTIBODY SPECIFICALLY BINDING TO N-TERMINAL REGION OF LYSYL-TRNA-SYNTHETASE EXPOSED ON CELL MEMBRANE Russian patent published in 2020 - IPC A61K39/395 C07K16/00 A61K39/00 G01N33/558 A61P35/04 

Abstract RU 2739393 C1

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to an antibody or fragment thereof, which specifically binds to the exposed to the extracellular medium N-terminal region of lysyl-tRNA-synthetase (KRS) and contains: a heavy chain variable region (VH) containing: complementarity-determining region 1 (CDR1) of a heavy chain comprising an amino acid sequence selected from a group consisting of SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 25 and SEQ ID NO: 37; complementarity-determining region 2 (CDR2) of the heavy chain, comprising an amino acid sequence selected from SEQ ID NO: 3, SEQ ID NO: 15, SEQ ID NO: 27 and SEQ ID NO: 39; and complementarity determining region 3 (CDR3) of heavy chain, comprising an amino acid sequence selected from SEQ ID NO: 5, SEQ ID NO: 17, SEQ ID NO: 29 and SEQ ID NO: 41; and a light chain variable region (VL) comprising: a complementarity determining region 1 (CDR1) of a light chain comprising an amino acid sequence selected from a group consisting of SEQ ID NO: 7, SEQ ID NO: 19, SEQ ID NO: 31 and SEQ ID NO: 43; complementarity-determining region 2 (CDR2) of a light chain comprising an amino acid sequence selected from SEQ ID NO: 9, SEQ ID NO: 21, SEQ ID NO: 33 and SEQ ID NO: 45; and a complementarity determining light chain region 3 (CDR3) comprising an amino acid sequence selected from SEQ ID NO: 11, SEQ ID NO: 23, SEQ ID NO: 35 and SEQ ID NO: 47, relates to a polynucleotide encoding an antibody or a fragment thereof, relates to a recombinant expression vector comprising a polynucleotide, also relates to a cell transformed with a recombinant vector, relates to a method of producing an antibody or a fragment thereof, relates to a method for specifically detecting an N-terminal region of an L-terminal region of lysyl-tRNA synthetase (KRS), relates to a pharmaceutical composition for inhibiting cancer metastasis and to a composition for preventing or treating a disease associated with migration of immune cells, also relates to a method of treating a disease associated with migration of immune cells.

EFFECT: group of inventions provides producing an antibody or a fragment thereof, specifically binding to an epitope, comprising a sequence of SEQ ID NO: 97 in N-terminal of lysyl-tRNA synthetase (KRS), where by binding to said epitope, the antibody reduced the level of KRS increased on the cell membrane of immune cells, and actually inhibited migration and infiltration of immune cells, having the effect of treating associated with such migration of diseases.

20 cl, 6 tbl, 35 dwg, 8 ex

Similar patents RU2739393C1

Title Year Author Number
ANTIBODY FOR SPECIFIC BINDING TO N-TERMINAL DOMAIN OF LYSYL-TRNA SYNTHETASE EXPOSED ON EXTRACELLULAR MEMBRANE 2019
  • Kim Sunghoon
  • Kwon Nam Hoon
RU2781304C1
PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIBODY SPECIFICALLY BINDING WITH THE N-TERMINAL OF LYSYL-TRNA SYNTHETASE AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY CELL MIGRATION 2018
  • Kwon Nam Hoon
  • Lee Jin Young
  • Kim Sunghoon
RU2749591C1
ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF 2020
  • Chung Hyejin
  • Yong Yeryoung
  • Park Kyeongsu
  • Park Eunyoung
  • Jung Ui-Jung
  • Lee Yangsoon
  • Kim Eunjung
  • Son Yong-Gyu
  • Son Wonjun
  • Ahn Seawon
  • Yeom Donghoon
  • Lee Chanmoo
  • Hong Junghyeon
  • Song Moo Young
  • Lee Eun-Jung
  • Lee Na Rae
  • Park Young Bong
  • Lee Eun-Jung
  • Kim Taewang
RU2831838C2
ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF 2020
  • Yan, Yan
  • Ge, Khu
  • Tao, Vejkan
RU2822550C2
BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODY AND USE THEREOF 2020
  • Yong Yeryoung
  • Jung Ui-Jung
  • Chung Hyejin
  • Park Kyeongsu
  • Son Wonjun
  • Lee Yangsoon
  • Kim Yeunju
  • Sung Eunsil
  • Kim Youngkwang
  • Pak Youngdon
  • Park Minji
  • Eom Jaehyun
  • Choi Hyoju
  • Song Moo Young
  • Lee Na Rae
  • Park Young Bong
  • Lee Eun-Jung
  • Lee Eun-Jung
RU2831836C2
BINDING MOLECULES, BINDING PD-L1 AND LAG-3 2017
  • Kempbell, Dzhejmi
  • Sendi, Nikol
  • Tyuna, Mikhriban
  • Vollerton Van Khork, Frantsiska
  • Everett, Keti Luiz
  • Gaspar, Migel
  • Kraman, Mettyu
  • Kmichik, Katarzhina
  • Farudi, Mustafa
  • Fosh, Natali
  • Khebeis, Barbara
RU2784388C2
ANTI-CLDN-18.2 ANTIBODY AND USE THEREOF 2021
  • Zhou, Yuehua
  • Zhang, Jing
  • Liu, Hui
  • Liu, Hongchuan
  • Wu, Hai
  • Yao, Jian
  • Huang, Lanqing
RU2829997C1
PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN 2018
  • Chang, Gregory, P.
  • Cheung, Ann, F.
  • Haney, William
  • Lunde, Bradley, M.
  • Prinz, Bianka
  • Grinberg, Asya
RU2816716C2
NEW ANTI-C-MET-ANTIBODY AND APPLICATION THEREOF 2018
  • Moon, Seung Kee
  • Lee, Kyung Woo
  • Jeon, Eun Ju
  • An, Ki Young
  • Choi, Eun Su
RU2751720C2
METHOD AND COMPOSITION FOR TREATING CANCER, DESTROYING METASTATIC CANCER CELLS AND PREVENTING METASTASES OF CANCER, USING ANTIBODIES TO END PRODUCTS OF INCREASED GLYCATION (AGE) 2017
  • Gruber, Lewis, S.
RU2728964C2

RU 2 739 393 C1

Authors

Kim Sunghoon

Shim Hyun Bo

Kwon Nam Hoon

Han Dae Young

Dates

2020-12-23Published

2018-03-27Filed